LatticeMLS
Menu

Module CC-16 · Version 1.0

How Lipid-Lowering Therapy Changes Laboratory Results

Common lipid-lowering drug classes change lipid panel and safety-monitoring results in identifiable patterns. Separating an expected treatment response from nonadherence, biological variation, and analytical or method problems lets a delayed or internally inconsistent lipid trend get verified before it is read as a treatment effect.

Your next section

Start section 1

Read without an account. Sign in to save.

Who this module is for

Clinical laboratory scientists and laboratory professionals who release and review chemistry results, working from CC-15 lipid-panel fundamentals.

Learning objectives

  • Map major lipid-lowering drug classes to the lipid fractions they commonly influence and the expected direction of change
  • Distinguish an expected treatment response from nonadherence or timing issues, biological variation, and analytical or method problems
  • Identify relevant safety-monitoring tests for lipid-lowering therapy while staying within the laboratory role

How completion works

Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.

Sources

12 sources

  1. 1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350.

    Source note · professional society guidance

  2. 2. FDA-approved prescribing information, ZETIA (ezetimibe) tablets. DailyMed.

    Source note · manufacturer labeling

  3. 3. FDA-approved prescribing information, TRICOR (fenofibrate) tablets. Accessdata Drugs@FDA.

    Source note · manufacturer labeling

  4. 4. FDA-approved prescribing information, VASCEPA (icosapent ethyl) capsules. DailyMed.

    Source note · manufacturer labeling

  5. 5. FDA-approved prescribing information, NEXLETOL (bempedoic acid) tablets. DailyMed.

    Source note · manufacturer labeling

  6. 6. FDA-approved prescribing information, LEQVIO (inclisiran) injection. Accessdata Drugs@FDA.

    Source note · manufacturer labeling

  7. 7. Interindividual variation in LDL-C reduction with evolocumab: analysis of FOURIER trial data. JAMA Cardiology.

    Source note · peer-reviewed literature

  8. 8. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of LDL-C lowering: ODYSSEY OUTCOMES trial. PMC.

    Source note · peer-reviewed literature

  9. 9. National Lipid Association. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024.

    Source note · professional society guidance

  10. 10. College of American Pathologists. Chemistry and Toxicology Checklist, item CHM.15225, eGFR and LDL Cholesterol Calculated Test Results (current edition).

    Source note · accreditation standard

  11. 11. Centers for Medicare & Medicaid Services. 42 CFR 493.1251, Test result records / result review for consistency with available data, and CMS interpretive guidance (State Operations Manual Appendix C).

    Source note · federal regulation

  12. 12. Guided case values compiled from the sources above.

    Source note · module-authored